

NCIC CLINICAL TRIALS GROUP

LUNG

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO

ROOM: CHURCHILL A

SATURDAY APRIL 30TH, 2011

10:00AM – 4:15 PM

CHAIRS: G. GOSS / Y. UNG

Objectives:

To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to the management of lung cancer

To cite and analyze recent results of lung cancer clinical studies conducted by or in collaboration with NCIC Clinical Trials Group

10:00 am	Welcome and Announcements	G. Goss
10:05 am	Subcommittee Reports: <ul style="list-style-type: none"> • Small Cell • Radiation • Mesothelioma and Thymoma • Correlative Sciences 	P. Ellis Y. Ung C. Lee M. Tsao
	Non-Small Cell Lung Cancer:	
10:35 am	<u>Surgical Adjuvant and Neoadjuvant and Locally Advanced Trials</u> <ul style="list-style-type: none"> • <u>BR.19</u> - Update on the results of the randomized trial of adjuvant gefitinib versus placebo after complete resection of Stage B, II IIIA NSCLC • <u>BRC.2</u> - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-IIIA NSCLC • <u>BRC.2E</u> A Prospective Economical Analysis of NCIC CTG BRC.2E /1505 a Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacuzumab for patients with completely resected Stage IB (>4cm) – IIIA Non-Small Cell Lung Cancer (NSCLC) • DISCUSSION • <u>BRC.5</u> - CALGB 140503 A Phase III randomized trial of lobectomy versus sub-lobar resection for small (<2cm) peripheral NSCLC 	G. Goss C. Butts N. Leigh Butts/Leigh Y. Ung

- 11:05 am **Advanced NSCLC:**
- BR.29 - A double blind randomized trial of cediranib versus placebo in patients receiving paclitaxel/carboplatin chemotherapy for the treatment of advanced or metastatic Non-Small Cell Lung cancer. S. Laurie
 - BR26 - A double blind placebo controlled trial of PF-804 in advanced NSCLC P. Ellis
- 11:35 am **Radiotherapy Study Update:** Y. Ung
- 12:05 pm **Small Cell Lung Cancer:**
- BR.28 - CONVERT – Once daily versus twice daily radiation for limited SCLC A. Bezjak
- 12:15–1:30 LUNCH**
- 1:30 pm **IND Studies:**
- IND.183 - Phase II trial of sunitinib in 2nd-line treatment of malignant mesothelioma S. Laurie
 - IND.190 - Phase I-II trial of etoposide/cisplatin + EGFR1 inhibitor in extensive stage SCLC P. Ellis
 - IND.196 - Phase I/II c-met inhibitor/erlotinib N. Leigh
- 2:10 pm **Report from the IND Committee and overview of new trials** G. Goss
- 2:30–2:50 BREAK**
- 2:50 pm **PRO, Economic and Secondary Analyses of Lung Trials**
- Quality of Life C. Lee
 - Economic analyses active and planned N. Leigh
 - Database analyses G. Goss
- 3:05 pm **Summary and Close** G. Goss